Long-Acting versus Short-Acting Opioids and Opioid-Related Disorders in Chronic Non-Cancer Pain: A Claims Data Analysis in Germany
Open Access
- 1 June 2026
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-12
Abstract
Background: Chronic non-cancer pain is common in primary care and may be managed with long-term opioid therapy. The German guideline “Long-term Use of Opioids for Chronic Non-Cancer Pain” provides recommendations for such treatment. The role of opioid formulation (long-acting vs. short-acting) and the association with opioid-related disorders remains underexplored. This study aims to explore associations between opioid formulation and opioid-related disorders in patients with chronic non-cancer pain receiving long-term opioid therapy in German general practices. Methods: We conducted a retrospective cross-sectional claims data analysis using data from one statutory health insurer in Baden-Württemberg (AOK), Germany, for the year 2021. The analysis included patients aged ≥ 18 years who received at least one oral or transdermal opioid prescription in all four quarters. Exclusion criteria were malignant diseases or palliative care. The outcome was opioid-related disorder (ICD-10 category F11.-). Multivariable logistic regression analyses were performed to identify predictors. Results: Multiple models were calculated. The main model included a total of 34,205 patients. The mean age was 70 years, and 65% were female. Overall, 3.1% of patients were diagnosed with an opioid-related disorder. Weak opioids were most frequently prescribed. Long-acting opioids predominated. Higher odds of opioid-related disorders were observed in patients with substance use disorders involving such as sedatives (OR = 5.6, 95% CI: 4.48– 7.01) or alcohol (OR = 2.2, 95% CI: 1.82– 2.66). Short-acting opioids (OR = 2.0, 95% CI: 1.53– 2.48) and combined long- and short-acting therapy (OR = 3.5, 95% CI: 2.38– 5.00) were associated with higher odds of opioid-related disorders compared with long-acting opioids (all p < 0.001). Conclusion: The results suggest that short-acting opioids, either alone or as part of combination therapy, may be more strongly associated with opioid-related disorders in patients with chronic non-cancer pain and long-term opioid therapy than long-acting opioids alone. Further research is needed to clarify these relationships and their underlying causes.Keywords
This publication has 42 references indexed in Scilit:
- Opioidverordnungen bei Versicherten ohne Krebserkrankung in Deutschland – Daten der BARMERDer Schmerz, 2024
- Comparative benefits and harms of individual opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised trialsBritish Journal of Anaesthesia, 2022
- Kritische Auseinandersetzung mit neuen Daten zur Prävalenz von Opioidgebrauchsstörungen bei Patienten mit chronischen Schmerzen in DeutschlandDer Schmerz, 2021
- Do Formulation and Dose of Long-Term Opioid Therapy Contribute to Risk of Adverse Events among Older Adults?Journal of General Internal Medicine, 2021
- European clinical practice recommendations on opioids for chronic noncancer pain – Part 2: Special situations*European journal of pain, 2021
- Empfehlungen der zweiten Aktualisierung der Leitlinie LONTSDer Schmerz, 2020
- Die US-amerikanische Opioidepidemie bedroht DeutschlandDer Schmerz, 2020
- Efficacy and harms of long‐term opioid therapy in chronic non‐cancer pain: Systematic review and meta‐analysis of open‐label extension trials with a study duration ≥26 weeksEuropean journal of pain, 2019
- Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis PainJAMA, 2018
- Long‐term opioid therapy for chronic non‐cancer pain in GermanyEuropean journal of pain, 2015